FindTrial
Sign In

Lacosamide in Neonatal Status Epilepticus

Efficacy of Lacosamide in Neonatal Status Epilepticus: A Randomized Controlled Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05291455
Enrollment
60
Registered
2022-03-22
Start date
2022-03-01
Completion date
2024-04-01
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

Lacosamide in neonatal status epilepticus

Detailed description

The study will assess the efficacy of Lacosamide in neonatal status epilepticus

Interventions

DRUGLacosamide

lacosamide will be given

DRUGPhenobarbital

phenobarbital will be given

Sponsors

Sherief Abd-Elsalam
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
No

Inclusion criteria

* neonates with status epilepticus

Exclusion criteria

* congenital anomalies or organ dysfunction

Design outcomes

Primary

MeasureTime frameDescription
number of children with cessation or improved duration of status epilepticus1 yearthe number of children with cessation or improved duration of status epilepticus

Countries

Egypt

Contacts

Primary Contactabeer salamah, lecturer
abeersalamah84@yahoo.com00201009221243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026